PhytoTech Medical Limited (ASX:PYL), the Australian owned Medical Cannabis (MC) company and the first MC company to list on the ASX, is pleased to announce the appointment of Dr Daphna Heffetz, as CEO for the wholly owned subsidiary company in Israel.
Phytotech Medical Limited (ASX:PYL), the Australian owned Medical Cannabis (MC) company and the first MC company to list on the ASX, is pleased to announce the appointment of Dr. Benad Goldwasser as a Non-Executive Director to its Board of Directors.
Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that it has signed an exclusive licensing and collaboration agreement with PhytoTech Medical Ltd. (ASX:PYL) for the development, manufacturing and marketing of a novel delivery system to enhance the bioavailability of cannabidiol (CBD) and/or THC, the active ingredients in cannabis, for the treatment of a variety of medical indications.
PhytoTech Medical Limited (ASX:PYL), the Australian owned Medical Cannabis (MC) company has today become the first MC company to list on the ASX. The company achieved a significant level of support from the investor community, successfully raising $5.9 million at $0.20 per share. The offer was significantly oversubscribed, demonstrating the high level of demand in the market to invest in MC stocks and the calibre of the offering by PhytoTech.
Phytotech Medical Limited (ASX:PYL) Israeli Legal Opinion - Medical Cannabis - Activities in Israel.
Phytotech's prospectus dated 20 November 2014 reveals that it proposes to be a leader in the business of medical cannabis delivery systems focusing on the commercialisation of cannabis delivery systems in the markets of USA, Canada, Israel and Europe (all markets which presently have regulated medical cannabis laws).
Official quotation of the Company's securities will commence at 2:00 pm Australian Eastern Daylight Savings Time ("AEDST") on Thursday, 22 January 2015. The Company has raised $5,932,410 pursuant to the offer under the prospectus dated 20 November 2014 and supplementary prospectus dated 5 January 2015 issued by the Company (together the "Prospectus") by the issue of 29,662,050 ordinary shares at an issue price of $0.20 per share.
